217 related articles for article (PubMed ID: 17403103)
1. Designs for phase I clinical trials with multiple courses of subjects at different doses.
Fan SK; Wang YG
Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
[TBL] [Abstract][Full Text] [Related]
2. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional dose finding in discrete dose space.
Wang K; Ivanova A
Biometrics; 2005 Mar; 61(1):217-22. PubMed ID: 15737096
[TBL] [Abstract][Full Text] [Related]
4. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
Braun TM; Thall PF; Nguyen H; de Lima M
Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of sequential dose-finding designs.
O'Quigley J
Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
[TBL] [Abstract][Full Text] [Related]
6. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
7. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation trial designs based on a molecularly targeted endpoint.
Hunsberger S; Rubinstein LV; Dancey J; Korn EL
Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
[TBL] [Abstract][Full Text] [Related]
9. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
10. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
12. [Accelerated titration design].
Minami H
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
[TBL] [Abstract][Full Text] [Related]
13. Improved up-and-down designs for phase I trials.
Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
15. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
16. Toxicity equivalence range design (TEQR): a practical Phase I design.
Blanchard MS; Longmate JA
Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
[TBL] [Abstract][Full Text] [Related]
17. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
18. Translation of innovative designs into phase I trials.
Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
[TBL] [Abstract][Full Text] [Related]
19. Designs for dose-escalation trials with quantitative responses.
Bailey RA
Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
[TBL] [Abstract][Full Text] [Related]
20. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
